Irene Scarfo
Overview
Explore the profile of Irene Scarfo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1739
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jing R, Scarfo I, Najia M, Lummertz da Rocha E, Han A, Sanborn M, et al.
Cell Stem Cell
. 2025 Mar;
PMID: 40088890
No abstract available.
2.
Frigault M, Graham C, Berger T, Ritchey J, Horick N, El-Jawahri A, et al.
Blood
. 2024 May;
144(11):1153-1167.
PMID: 38781564
We report a first-in-human clinical trial using chimeric antigen receptor (CAR) T cells targeting CD37, an antigen highly expressed in B- and T-cell malignancies. Five patients with relapsed or refractory...
3.
Ormhoj M, Scarfo I, Cabral M, Bailey S, Lorrey S, Bouffard A, et al.
Clin Cancer Res
. 2024 May;
30(10):2286.
PMID: 38745479
No abstract available.
4.
Wehrli M, Guinn S, Birocchi F, Kuo A, Sun Y, Larson R, et al.
Clin Cancer Res
. 2024 Feb;
30(9):1859-1877.
PMID: 38393682
Purpose: Targeting solid tumors with chimeric antigen receptor (CAR) T cells remains challenging due to heterogenous target antigen expression, antigen escape, and the immunosuppressive tumor microenvironment (TME). Pancreatic cancer is...
5.
Larson R, Kann M, Graham C, Mount C, Castano A, Lee W, et al.
Nat Commun
. 2023 Nov;
14(1):7509.
PMID: 37980341
Chimeric Antigen Receptor (CAR) T cells directed to B cell maturation antigen (BCMA) mediate profound responses in patients with multiple myeloma, but most patients do not achieve long-term complete remissions....
6.
Schmidts A, Srivastava A, Ramapriyan R, Bailey S, Bouffard A, Cahill D, et al.
Neurooncol Adv
. 2023 Feb;
5(1):vdac185.
PMID: 36751672
Background: Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has...
7.
Jing R, Scarfo I, Najia M, Lummertz da Rocha E, Han A, Sanborn M, et al.
Cell Stem Cell
. 2022 Aug;
29(8):1181-1196.e6.
PMID: 35931029
Human induced pluripotent stem cells (iPSCs) provide a potentially unlimited resource for cell therapies, but the derivation of mature cell types remains challenging. The histone methyltransferase EZH1 is a negative...
8.
Leick M, Silva H, Scarfo I, Larson R, Choi B, Bouffard A, et al.
Cancer Cell
. 2022 Apr;
40(5):494-508.e5.
PMID: 35452603
Chimeric antigen receptor (CAR) T cell therapy is effective in lymphoid malignancies, but there has been limited data in myeloid cancers. Here, we start with a CD27-based CAR to target...
9.
Larson R, Kann M, Bailey S, Haradhvala N, Montero Llopis P, Bouffard A, et al.
Nature
. 2022 Apr;
604(7906):563-570.
PMID: 35418687
Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of haematologic malignancies, but it has shown limited efficacy against solid tumours. Solid tumours may have cell-intrinsic...
10.
Bailey S, Vatsa S, Larson R, Bouffard A, Scarfo I, Kann M, et al.
Blood Cancer Discov
. 2022 Jan;
3(2):136-153.
PMID: 35015685
Significance: Blocking IFNγ in CAR T cells does not impair their cytotoxicity against hematologic tumor cells and paradoxically enhances their proliferation and reduces macrophage-mediated cytokines and chemokines associated with CRS....